Ingredientes10-Hydroxy-2-decenoic acid (abbreviated 10-HDA) is also known by several synonyms: trans-10-hydroxy-2-decenoic acid, 10-hydroxy-trans-2-decenoic acid, (E)-10-hydroxydec-2-enoic acid, queen bee acid, royal jelly acid, and by the lipid shorthand FA 10:1;O. Its CAS numbers are 14113-05-4 (for the trans/E-isomer) and synonyms include 10-HDA, 10-HAD, 10H2DA, "Royal Jelly Acid," and "Queen Bee Acid." Its molecular formula is C₁₀H₁₈O₃, with a formula weight of 186.3 g/mol.
10-HDA is an α,β-unsaturated medium-chain carboxylic acid containing a terminal hydroxyl group. It is classified as an alpha,beta-unsaturated monocarboxylic acid, a straight-chain fatty acid, a hydroxy monounsaturated fatty acid, and an omega-hydroxy medium-chain fatty acid. The compound features a ten-carbon backbone with a trans (E-configuration) carbon–carbon double bond between C-2 and C-3, a carboxylic acid group at C-1, and a hydroxyl group at C-10 (the terminal carbon). In its pure, isolated form it presents as a crystalline solid, soluble in DMF and DMSO at approximately 30 mg/mL and in ethanol at approximately 20 mg/mL.
10-HDA is an unsaturated fatty acid found in royal jelly, produced from the hypopharyngeal and mandibular gland secretions of honeybees. Royal jelly is the sole food administered by young workers or nurse bees of the common honey bee species Apis mellifera to female larvae destined to become queens. Larvae destined to become drones (males) or workers receive royal jelly only during the first three days of their existence, after which they receive a different food.
10-HDA is a significant quality parameter for royal jelly, constituting approximately 0.5%–3.5% of the dry weight of royal jelly. Biochemically, 10-HDA is obtained by terminal hydroxylation of trans-2-decenoic acid, a medium-chain α,β-unsaturated carboxylic acid. In queen-right colonies, workers predominantly produce 10-HDA and 10-HDAA by their mandibular glands.
Uniqueness as a natural product is a key characteristic of 10-HDA. Major royal jelly proteins (MRJPs) are, together with 10-hydroxy-2-decenoic acid (10-HDA), key substances of royal jelly due to their different biological properties; in particular, 10-HDA is a unique substance in this product.
Royal jelly as a whole consists mainly of water (50–56%), proteins (18%), carbohydrates (15%), lipids (3–6%), minerals (1.5%), and vitamins. 10-HDA is available in commerce both as a constituent of raw royal jelly preparations and as an isolated, purified compound for research purposes. Raw royal jelly is perishable and typically stored frozen or refrigerated. Lyophilized (freeze-dried) royal jelly is a concentrated form used in capsules, tablets, and powders. Lipids constitute about 7–18% of royal jelly, significantly contributing to its biological activities, and are predominantly composed of short hydroxy fatty acids with 8–12 carbon atoms, with key components including 10-hydroxy-2-decenoic acid (10H2DA) and sebacic acid.
The presence and concentration of 10-HDA is used internationally as a quality and authenticity marker for royal jelly products. Countries such as Australia, Korea, Japan, and Thailand use the presence of 10-HDA as an indicator of pure royal jelly; according to Thai specifications, the amount of 10-HDA should not be less than 1.5% and 0.16% (w/w), respectively, for royal jelly and royal jelly products.
Synthetic and biosynthetic production pathways have also been developed. In biosynthetic approaches, a two-step enzymatic process uses a P450 enzyme (CYP153A33/M228L-CPRBM3) to efficiently catalyze the conversion of trans-2-decenoic acid to 10-HDA via terminal hydroxylation. Recombinant brewing yeast has also been used, with 10-HDA synthesized by fermentation using trans-2-decenoic acid as the substrate.
The use of royal jelly — and by extension its constituent 10-HDA — is rooted in the broader tradition of apitherapy. Royal jelly has been used since ancient times in traditional medicine, cosmetics, and as a functional food due to its high nutritional value. Royal jelly has been historically employed as a health enhancer and is still very relevant in China due to the tradition of medicine and apitherapy.
It is important to note that in traditional contexts, it was royal jelly as a whole substance — not isolated 10-HDA — that was used. The identity of 10-HDA as the principal bioactive lipid component was only established in the mid-twentieth century through modern analytical chemistry. The formal identification of 10-hydroxy-Δ²-decenoic acid in royal jelly was published in Nature in 1959 by Barker, Foster, Lamb, and Hodgson, and an independent earlier isolation was reported by Butenandt and Rembold in 1957. Nowadays, royal jelly is mainly consumed as a functional food or is found in supplements and other formulations for its health-beneficial properties.
Japan has had a particularly prominent tradition of royal jelly consumption as a tonic and health supplement, with documented evaluation of its medical efficacy referenced as early as the 1985 International Congress of Apiculture in Nagoya. Royal jelly is used in many different fields such as cosmetics, health, and food. Traditional applications attributed to royal jelly preparations include promotion of vitality and energy, support of the immune system, anti-aging effects, and skin health — claims that modern research has since investigated at the molecular level with respect to 10-HDA specifically.
Royal jelly has been used since ancient times in traditional medicine; its main bioactive substances are royalactin and 10-hydroxy-2-decenoic acid (10-HDA). 10-HDA is the trans isomeric form and the predominant fatty acid constituent. The major fatty acid among the short-chain hydroxy fatty acids in royal jelly is trans-10-HDA.
The anti-inflammatory activity of 10-HDA has been characterized primarily through the NF-κB signaling pathway. 10-HDA was proved to inhibit TLR4-induced immune cell activation and inflammatory cytokine expression in LPS-activated macrophages via reducing NF-κB expression. In prior studies, 10-HDA inhibited nitric oxide (NO) production in a dose-dependent manner, reduced the secretion of TNF-α and IL-1β, and increased the anti-inflammatory cytokine IL-10 in LPS-stimulated RAW 264.7 cells, indicating that 10-HDA is able to attenuate inflammation and the inflammatory polarization of M1 macrophages.
10-HDA modulates inflammatory pathways by inhibiting NF-κB and reducing HDAC activity; it also attenuates the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-8. In the context of cardiac injury, 10-HDA suppressed TLR4 and MyD88 upregulation, decreased IκBα phosphorylation and degradation, prevented NF-κB nuclear translocation, and downregulated pro-inflammatory cytokine expression; co-immunoprecipitation assay confirmed reduced TLR4–MyD88 interaction, and experimental results from TAK242 intervention demonstrated that 10-HDA mediates its cardioprotective effects primarily via inhibition of the TLR4/MyD88/NF-κB pathway.
It has been reported that single large-dose administration of 10-HDA stimulates phosphorylation of AMPK-α in myoblast L6 cells, and long-term administration significantly increases p-AMPK-α protein in skeletal muscles. In human brain microvascular endothelial cells, 10-HDA inhibits LPS-induced blood–brain barrier dysfunction by activating the AMPK-α pathway and its downstream PI3K/AKT pathway, thereby reducing the expression of chemokines and matrix metalloproteinases. Furthermore, 10-HDA suppresses the expression of the Aquaporin 9 gene in HepG2 cells by promoting the phosphorylation of AMPK, thereby reducing glucose levels in hepatocytes.
A particularly significant mechanism identified for 10-HDA is its ability to act as a histone deacetylase inhibitor (HDACi). Royal jelly has histone deacetylase inhibitor (HDACi) activity; the fatty acid (E)-10-hydroxy-2-decenoic acid (10HDA), which accounts for up to 5% of royal jelly, harbors this HDACi activity. Furthermore, 10HDA can reactivate the expression of epigenetically silenced genes in mammalian cells. Thus, the epigenetic regulation of queen-bee development is probably driven, in part, by HDACi activity in royal jelly.
Evidence indicates that small molecules in royal jelly can modulate gene expression in mammalian cells, and the fatty acid 10-hydroxy-2-decenoic acid (10-HDA) has been previously associated with the inhibition of histone deacetylase enzymes (HDACs). 10-HDA acts as a histone deacetylase (HDAC) inhibitor, leading to epigenetic growth arrest and apoptosis. This mechanism is biologically relevant to bee caste differentiation: worker and queen bees are genetically indistinguishable; however, queen bees are fertile, larger, and have a longer lifespan than their female worker counterparts. Differential feeding of larvae with royal jelly controls this caste switching, and there is emerging evidence that the queen-bee phenotype is driven by epigenetic mechanisms.
10-HDA, a major fatty acid component of royal jelly, is known to have various pharmacological effects, with its antitumor activity being especially noteworthy. The compound targets multiple cancer-relevant pathways. It reduces cell growth and activates cell death in malignant cells. Royal jelly is hence believed to have anti-cancer effects on tumor development and to have protective qualities against toxic medication side effects; via the control of several cancer-related pathways, royal jelly and one of its key constituents, 10-HDA, can reduce tumor development and the migration of malignant cells.
10-HDA is an orally available royal jelly component that potently inhibits osteoclastogenesis; it binds to free fatty acid receptor 4 (FFAR4) on osteoclasts, which inhibits RANKL (receptor activator of nuclear factor-κB ligand), thereby attenuating the induction of nuclear factor of activated T cells (NFAT) c1.
10-Hydroxy-Δ²-decenoic acid, the major component of the lipid fraction of royal jelly, exhibits antibiotic activity against many bacteria and fungi. This fatty acid is less than one-fourth as active as penicillin against Micrococcus pyogenes and less than one-fifth as active as chlortetracycline against Escherichia coli. It also slows the growth rate of Neurospora sitophila and some unidentified molds. The salt of this compound is considerably less active than the free acid.
10-HDA has shown promising anti-neuroinflammatory, blood–brain barrier (BBB)-preserving, and neurogenesis-promoting properties. 10-HDA facilitates differentiation of neurons from neural stem/progenitor cells and promotes collagen production by skin fibroblasts at concentrations of 100 µM and 1.5 mM, respectively.
10-HDA can activate PPARα signaling, promoting epidermal differentiation and increasing the expression of intercellular lipids, thereby accelerating the formation of the cornified envelope and repairing the skin barrier. Additionally, 10-HDA can improve mitochondrial function by enhancing the efficiency of the mitochondrial electron transport chain, reducing oxidative damage, enhancing energy metabolism in the dermal layer of the skin, and delaying aging.
The earliest scientific documentation of 10-HDA's biological activity concerned its antimicrobial properties. Studies dating to 1959 established that 10-hydroxy-Δ²-decenoic acid, the major component of the lipid fraction of royal jelly, exhibits antibiotic activity against many bacteria and fungi.
More recent work has extended these observations. In cell-culture and minimum inhibitory concentration (MIC) assays, 10-HDA acted as a potent bactericide against animal- or human-specific pathogens, including Staphylococcus aureus, Streptococcus alactolyticus, Staphylococcus intermedius B, Staphylococcus xylosus, Salmonella choleraesuis, Vibrio parahaemolyticus, and hemolytic Escherichia coli. Royal jelly, 10-H2DA, 10-HDAA, and sebacic acid showed potent antileishmanial effects with IC₅₀ values ranging from 2.4 to 8.4 µg/mL.
Evidence strength: Antimicrobial activity is well-characterized in vitro but the clinical (human) evidence for 10-HDA as a standalone antimicrobial agent is absent. All findings are from cell-free, cell-culture, or animal-based assays.
Multiple in vitro and animal studies have investigated 10-HDA's anti-inflammatory activity. In human colon cancer (WiDr) cells, 10-HDA decreased IL-8 by 75% and reduced TNF-α and IL-1β levels, while simultaneously increasing IL-1ra, an anti-inflammatory cytokine.
In an animal colitis model, a study explored the effects of 10-HDA on dextran sodium sulfate (DSS)-induced ulcerative colitis (UC); forty male C57BL/6 mice were randomly divided into five experimental groups (control, DSS, DSS + 25 or 100 mg kg⁻¹ d⁻¹ 10-HDA, and DSS + 200 mg kg⁻¹ d⁻¹ mesalazine), with UC induced using 2.5% DSS in drinking water for 7 days, and UC mice orally administered 10-HDA or mesalazine per day. 10-HDA reduced DSS-induced pathological damage, reactive oxygen species (ROS) accumulation, neutrophil infiltration, and cytokine production in colonic tissue.
Evidence strength: The anti-inflammatory activity of 10-HDA is substantiated across multiple in vitro systems and in rodent models. No dedicated human clinical trials for 10-HDA in inflammatory conditions have been identified in the literature as of this writing.
Interest in the antitumor activity of 10-HDA extends back to the 1960 publication of Townsend et al. in Cancer Research, which first described in vitro antitumor activity of this fatty acid from royal jelly. Subsequent research has explored mechanisms in multiple cancer cell lines.
In a study of human hepatoma (HepG2) cells, HepG2 cell viability was markedly reduced following exposure to 10-HDA in a dose-dependent manner; the calculated CC₅₀ value of 10-HDA was 59.6 µg/mL for HepG2 cells and 106.4 µg/mL for normal THLE-3 cells. The results confirmed the potent in vitro cytotoxic effects of 10-HDA on HepG2 cells with no significant cytotoxic effects on normal cells; the induction of apoptosis via different pathways was determined as one of the principal mechanisms of action of 10-HDA against HepG2 cells.
At the mechanistic level, the levels of protein expression of Caspase-3, PARP, and Bax were markedly elevated following exposure of HepG2 cells to 10-HDA, while the level of protein expression of Bcl-2 was markedly reduced. Additionally, biochemical assays and gene expression analyses evaluated the functional effects of 10-HDA in two human cancer cell lines (HCT116 and MDA-MB-231), examining expression levels of class I HDAC-encoding genes after 72 hours of in vitro exposure to 10-HDA at 100 µM.
Evidence strength: All anticancer evidence for 10-HDA is in vitro (cell culture). No human clinical trials on 10-HDA or royal jelly in cancer treatment have been identified. The findings are mechanistically interesting but remain preclinical. Additional surveys must be performed to clearly understand the mechanisms of action and safety of this fatty acid.
10-HDA, a unique hydroxy fatty acid in royal jelly, has shown promising anti-neuroinflammatory, blood–brain barrier (BBB)-preserving, and neurogenesis-promoting properties; a review discusses 10-HDA as a potential intervention nutrient in the context of metabolic syndrome and its relationship to Alzheimer's disease risk.
In traumatic brain injury (TBI) models, 10-HDA, the major fatty acid in royal jelly, exhibits antibacterial, anti-inflammatory, and antioxidant properties, suggesting its potential therapeutic benefits for traumatic brain injury. A study demonstrated the neuroprotective effect of 10-HDA in TBI and uncovered a novel molecular mechanism, showing that 10-HDA reduces copper-mediated neuronal pyroptosis by regulating ATP7A expression. The administration of 10-HDA effectively prevents the destruction of the BBB, maintains copper homeostasis by mediating the expression of ATP7A, and then inhibits the pyroptosis of neurons, playing a neuroprotective role.
In the context of cognitive function in diabetes, the intervention of royal jelly and 10-HDA not only significantly lowered blood glucose and blood lipids in diabetic mice and reduced hippocampal tissue damage, but also further improved the learning and memory abilities of mice through appropriately regulating autophagy. However, despite the neuroprotective effects of royal jelly and 10-HDA having been largely verified in diabetic mouse models, further well-designed randomized trials based on human participants and dose-response correlation analysis between 10-HDA intervention and cognitive performance are still needed.
Antidepressant-like activity of 10-HDA has been reported in a stress-inducible depression model in mice (Ito et al., Evidence-Based Complementary and Alternative Medicine, 2012), though this too is a preclinical finding.
Evidence strength: Neuroprotective, neurogenic, and antidepressant effects of 10-HDA are supported by multiple in vitro and animal studies. Human clinical data specific to isolated 10-HDA are absent.
10-HDA is a principal active ingredient of royal jelly, and several recent studies have demonstrated that 10-HDA has potential anti-type 2 diabetes mellitus (T2DM) properties. To evaluate the anti-T2DM effect of 10-HDA, researchers used a high-fat diet (HFD) combined with streptozotocin (STZ) injection to establish a diabetes model; mice were divided into four groups (8 mice per group), and the 10-HDA and T2DM + 10-HDA groups were administered intragastrically 10-HDA (100 mg per kg body weight) daily for 4 weeks.
In nonalcoholic fatty liver disease (NAFLD) research, in mice fed a methionine-choline-deficient (MCD) diet, 10-HDA treatment significantly reduced hepatic steatosis, hepatocellular injury, apoptosis, inflammatory response, and fibrosis.
An earlier study published in the Journal of Veterinary and Medical Science (2017) reported that 10-HDA improved hyperglycemia and insulin resistance in obese/diabetic KK-Ay mice.
Evidence strength: Anti-diabetic and anti-metabolic-syndrome effects are supported in rodent models and cell lines. No published human clinical trials specifically administering isolated 10-HDA for diabetes or obesity have been identified.
A pilot animal study investigated the effects of 10-hydroxy-2-decenoic acid (10H2DA) and 10-hydroxydecanoic acid (10HDAA) in ovariectomized rats as a model of postmenopausal bone loss. Femoral bone mineral density was significantly lower in the ovariectomized group than in the sham group (p < 0.01); administration of 10H2DA or 10HDAA did not ameliorate bone loss after ovariectomy; and in addition, administration of these fatty acids diminished femur bone stiffness in ovariectomized rats. These results from a pilot animal study suggest that the effects of 10-HDA on bone are not straightforwardly protective and warrant further investigation.
In contrast, receptor-level data suggest a mechanism for potential bone protection: 10-HDA is an orally available royal jelly component that potently inhibits osteoclastogenesis; it binds to free fatty acid receptor 4 (FFAR4) on osteoclasts, inhibiting RANKL and thereby attenuating the induction of NFATc1; and 10-HDA inhibits bone resorption in ovariectomized mice.
Small-molecule 10-hydroxy-2-decenoic acid suppresses cartilage degeneration and relieves pain in chondrocytes and cartilage explants from osteoarthritis patients, and in surgery-induced or naturally aged male mice. Mechanistically, 10-hydroxy-2-decenoic acid alleviates cellular senescence through the ERK/p53/p21 and GSK3β/p16 pathways in chondrocytes.
Evidence strength: Bone-related evidence is mixed; in vitro and some animal data suggest osteoclast-inhibiting and cartilage-protective effects, while a pilot ovariectomy study did not confirm protection of bone mineral density. No human data exist.
An in vitro study in human dermal fibroblasts reported that 10-HDA prevented ultraviolet A-induced damage, cytotoxicity, reactive oxygen species, and cellular senescence by inhibiting expression of MMP1 and MMP-3 and inhibiting activation of the JNK and p38 MAPK pathways.
Researchers identified 10-HDA as an active compound that induced the expression of NQO1 and protected the skin against oxidative stress; NQO1 is involved in antioxidation and detoxification metabolism, and royal jelly was found to protect against the epidermal stress caused by UVB and menadione through the upregulation of NQO1 by 10-HDA.
Transcriptomic results suggested that 10-HDA promoted epidermal barrier function and dermal energy metabolism; within the epidermal layer, 10-HDA activated PPARα signaling and enhanced the expression of downstream genes IVL, LOR, FLG, and TGM1, thereby promoting epidermal differentiation, and it upregulated the expression of SPT, GBA, and ACACA, increasing intercellular lipid content and accelerating the formation of the cornified envelope.
Evidence strength: Skin-related effects of 10-HDA are supported by in vitro and mechanistic data. A proprietary topical preparation containing 10-HDA ("Hydroxydecine") was the subject of a clinical study in UV-induced xerosis (ResearchGate, 2011), but the full text of that clinical study was not accessible for detailed appraisal in this review. In vitro evidence is consistent and mechanistically detailed; human clinical validation remains limited.
Royal jelly is known to contain 10-hydroxydecanoic acid (10HDAA), a related compound, which has been shown to have immune activation properties, including the promotion of M cell differentiation. For 10-HDA itself, immunomodulatory activity operates through T-cell and macrophage pathways. At lower concentrations, certain royal jelly extracts stimulated T-cell proliferation triggered by concanavalin A, accompanied by an increase in the production of interleukin-2 (IL-2); higher concentrations of the trans-10-hydroxydec-2-enoic acid fraction inhibited T-cell proliferation. This bidirectional, concentration-dependent immunomodulatory effect is an important nuance.
Evidence strength: Immunomodulatory effects are characterized in vitro and in rodent models. The dose-dependency of inhibitory versus stimulatory effects adds complexity. Clinical evidence in humans is lacking for isolated 10-HDA.
Royal jelly produced by honeybees has been reported to possess diverse health-beneficial properties and has been implicated to have a function in longevity across diverse species; 10-HDA, the major lipid component of royal jelly, was previously shown to increase the lifespan of Caenorhabditis elegans. 10-HDA has longevity-promoting effects in C. elegans at a concentration of 25 µM.
The mechanisms underlying lifespan extension in C. elegans were found to involve dietary restriction signaling and the target of rapamycin (TOR) pathway (Honda et al., Journal of Aging Research, 2015, PMC4350847).
10-HDA has a role as an animal metabolite and a geroprotector.
Evidence strength: Longevity effects are established in the invertebrate model organism C. elegans. Whether these effects translate to mammals or humans is unknown; no lifespan-extension or anti-aging clinical trials of 10-HDA in humans have been published.
Increased activation and proliferation of fibroblast-like synoviocyte (FLS) cells, along with development of pannus that invades nearby bone and cartilage, are characteristic features of rheumatoid arthritis (RA). Inhibition of FLS cell growth is an important therapeutic goal. Prior research indicated that 10-HDA could potentially reduce FLS cell growth; recent findings highlighted the inverse relationship between dosage and time with regard to the viability and histone deacetylase (HDAC) activity of FLS cells, opening up new possibilities for the development of HDAC inhibitors as a potential treatment option for RA. 10-HDA was implicated in inhibiting the target genes of the PI3K-AKT pathway, thereby suggesting its potential as an alternative treatment option for RA.
Evidence strength: Evidence is in vitro and preclinical only.
For menopausal symptoms, human trials have examined royal jelly as a whole product; in a double-blind randomized controlled trial of 200 postmenopausal women, royal jelly treatment was examined. However, this trial examined royal jelly as a whole product, not isolated 10-HDA; the specific contribution of 10-HDA to outcomes in that trial cannot be separately established from currently available data.
Although previous studies have demonstrated that royal jelly may have estrogenic properties and prevent postmenopausal bone loss, the underlying mechanisms are not fully understood. The estrogenic activity attributed to royal jelly has been linked, in part, to fatty acids including 10-HDA, but direct evidence for 10-HDA's estrogenic activity in human studies is not established.
The following dosages are reported directly from published scientific studies. They are not clinical recommendations, and no human therapeutic dose for isolated 10-HDA has been established by regulatory authorities or in clinical trials.
In the context of royal jelly products, 10-HDA content is often standardized and reported as a percentage of product weight. 10-HDA constitutes approximately 0.5%–3.5% of the dry weight of royal jelly. Analytical studies have measured 10-HDA concentrations in royal jelly samples ranging from approximately 0.35% to 2.44% by weight (as reported in near-infrared spectroscopy validation work).
Despite numerous health-related benefits being observed, the oral consumption of royal jelly has been reported to potentially trigger severe allergic symptoms in humans, involving acute asthma, anaphylaxis, and even death, which inevitably causes relevant safety concerns and limits its medical application. Royal jelly can cause anaphylaxis in people who are allergic to bee products; otherwise, adverse events are typically mild.
These allergic reactions are attributed to royal jelly proteins (primarily the major royal jelly proteins), and individual contribution of 10-HDA to immunoglobulin E-mediated sensitization has not been separately characterized in clinical studies.
Royal jelly should not be taken with antihypertensive medications/supplements or warfarin. These interactions are attributed to the royal jelly preparation as a whole, not specifically to isolated 10-HDA. The evidence base for these interactions derives from case reports and pharmacological plausibility rather than controlled interaction studies.
In a placebo-controlled clinical trial of 66 subjects with mild cognitive impairment, treatment with a dietary supplement combining 750 mg lyophilized royal jelly, 120 mg standardized extracts of ginkgo, and 150 mg Panax ginseng for 4 weeks did not result in any serious adverse events; only mild nausea was reported. This trial used a combined product, not isolated 10-HDA.
As noted in the immunomodulatory section, higher concentrations of trans-10-hydroxydec-2-enoic acid inhibited T-cell proliferation in vitro. The physiological relevance of concentration-dependent immunosuppressive effects at orally achievable doses in humans has not been systematically evaluated.
A pilot animal study found that administration of 10-HDA and 10-HDAA diminished femur bone stiffness in ovariectomized rats — a finding that warrants consideration and further investigation before extrapolation to human use.
No dedicated human safety pharmacology study or phase I clinical trial for isolated 10-HDA has been identified in the published literature. Safety data for 10-HDA in humans are entirely inferential from royal jelly product safety, as 10-HDA has not been studied as a standalone pharmaceutical agent in clinical settings. Although the mechanisms of action of 10-HDA have not been fully studied, additional surveys must be performed to clearly understand both the mechanisms of action and safety of this fatty acid.
Condiciones de salud que 10-hydroxy-2-decanoic acid puede ayudar a apoyar.
The principal unique fatty acid of royal jelly (10-HDA), 10-hydroxy-2-decanoic acid has documented antimicrobial, anti-inflammatory, and immunomodulatory properties. It is the primary bioactive marker compound of royal jelly used traditionally across Asia and Europe for convalescent restoration of vitality and energy.
Sistemas corporales que 10-hydroxy-2-decanoic acid puede ayudar a apoyar.
Volver